GSK1016790A是一种TRPV4激动剂,可以修复糖尿病引起的精子发生器功能障碍
Xingqi Meng1, Xiaohan Tang1, Lixuan Peng1
1Clinical Anatomy & Reproductive Medicine Application Institute, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Reproductive sciences (Thousand Oaks, Calif.)
|February 27, 2025
概括
用GSK1016790A激活过渡受体潜在化物4 (TRPV4) 改善了糖尿病小鼠的精子参数,并减少了糖尿病小鼠的亡. 这表明TRPV4激活可以防止糖尿病丸损伤和精子生成功能障碍.
科学领域:
- 生殖生物学 生殖生物学
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 糖尿病丸损伤会损害精子生成和性功能.
- 暂时受体潜能瓦尼洛伊德4 (TRPV4) 与糖尿病并发症和亡有关.
- 了解TRPV4的作用对于解决糖尿病生殖问题至关重要.
研究的目的:
- 为了研究TRPV4激动剂GSK1016790A的治疗潜力.
- 评估对糖尿病小鼠的精子参数,细胞亡和丸组织病理学的影响.
- 阐明TRPV4在糖尿病丸损伤中的保护机制.
主要方法:
- 在雄性ICR小鼠中,使用链毒素 (STZ) 诱导糖尿病.
- 在小鼠体内注射了GSK1016790A或盐水.
- 在8周后分析了丸组织和精子参数.
主要成果:
- 由STZ诱导的糖尿病降低了丸TRPV4表达,精子数和活力.
- 糖尿病小鼠表现出精子变形和亡的增加.
- GSK1016790A治疗通过增加TRPV4表达来逆转这些负面影响.
结论:
- 激活TRPV4可以改善糖尿病小鼠丸的亡.
- 治疗TRPV4激动剂可以缓解由糖尿病引起的精子生成功能障碍.
- 向TRPV4可能为糖尿病生殖并发症提供一种新的治疗策略.
相关概念视频
Spermatogenesis
102.0K
Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male...
102.0K
Dipeptidyl Peptidase 4 Inhibitors
161
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
161
Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290


